References
- Hosoi Y, Uno Y, Murayama N, et al. (2012). Monkey liver cytochrome P450 2C19 is involved in R- and S-warfarin 7-hydroxylation. Biochem Pharmacol 84:1691–5
- Koyanagi T, Nakanishi Y, Murayama N, et al. (2015). Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole, and metoprolol in cynomolgus monkeys using in vitro–in vivo correlation. Xenobiotica 45:312–21
- Nishiyama S, Suemizu H, Shibata N, et al. (2015). Simulation of human plasma concentrations of thalidomide and primary 5-hydroxylated metabolites explored with pharmacokinetic data in humanized TK-NOG mice. Chem Res Toxicol 28:2088–90
- Poulin P, Haddad S. (2013). Hepatocyte composition-based model as a mechanistic tool for predicting the cell suspension: aqueous phase partition coefficient of drugs in in vitro metabolic studies. J Pharm Sci 102:2806–18
- Rendic S, Guengerich FP. (2012). Contributions of human enzymes in carcinogen metabolism. Chem Res Toxicol 25:1316–83
- Sakai C, Iwano S, Yamazaki Y, et al. (2014). Species differences in the pharmacokinetic parameters of cytochrome P450 probe substrates between experimental animals, such as mice, rats, dogs, monkeys, and microminipigs, and humans. J Drug Metab Toxicol 5:173
- Scordo MG, Pengo V, Spina E, et al. (2002). Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72:702–10
- Shida S, Utoh M, Murayama N, et al. (2015). Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling. Xenobiotica 45:881–6
- Shida S, Yamazaki H. (2016). Human plasma concentrations of five cytochrome P450 probes extrapolated from pharmacokinetics in dogs and minipigs using physiologically based pharmacokinetic modeling. Xenobiotica 46:759–64
- Takahashi H, Kashima T, Nomizo Y, et al. (1998). Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 63:519–28
- Uehara S, Murayama N, Nakanishi Y, et al. (2011). Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys. J Pharmacol Exp Ther 339:654–61
- Uno Y, Matsushita A, Murayama N, Yamazaki H. (2015a). Genetic polymorphism of cynomolgus and rhesus macaque CYP2C9. Drug Metab Pharmacokinet 30:130–2
- Uno Y, Matsushita A, Shukuya M, et al. (2014a). CYP2C19 polymorphisms account for inter-individual variability of drug metabolism in cynomolgus macaques. Biochem Pharmacol 91:242–8
- Uno Y, Uehara S, Kohara S, et al. (2014b). Polymorphisms of CYP2D17 in cynomolgus and rhesus macaques: an evidence of the genetic basis for the variability of CYP2D-dependent drug metabolism. Drug Metab Dispos 42:1407–10
- Uno Y, Uehara S, Yamazaki H. (2016). Utility of non-human primates in drug development: comparison of non-human primate and human drug-metabolizing cytochrome P450 enzymes. Biochem Pharmacol 121:1–7
- Utoh M, Suemizu H, Mitsui M, et al. (2016). Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling. Xenobiotica 46:1049–55
- Utoh M, Yoshikawa T, Hayashi Y, et al. (2015). Slow R-warfarin 7-hydroxylation mediated by P450 2C19 genetic variants in cynomolgus monkeys in vivo. Biochem Pharmacol 95:110–4
- Yamazaki H, Kunikane E, Nishiyama S, et al. (2015). Human plasma concentrations of tolbutamide and acetaminophen extrapolated from in vivo animal pharmacokinetics using in vitro human hepatic clearances and simple physiologically based pharmacokinetic modeling for radio-labeled microdose clinical studies. Radioisotopes 64:509–19
- Yamazaki H, Suemizu H, Mitsui M, et al. (2016). Combining chimeric mice with humanized liver, mass spectrometry, and physiologically-based pharmacokinetic modeling in toxicology. Chem Res Toxicol 29:1903–11